Monopar Therapeutics advances cancer treatments with positive preclinical results and financial improvements

From GlobeNewswire: 2024-08-09 08:00:00

Monopar Therapeutics is initiating a Phase 1 clinical trial for its MNPR-101 radiopharmaceutical, designed to treat various cancers, with promising preclinical results showing tumor elimination. The company also secured a long-term supply agreement for actinium-225 and conducted a successful reverse stock split to regain compliance with Nasdaq listing requirements.

The company reported net losses of $1.7 million for the second quarter of 2024, compared to $2.2 million in the second quarter of 2023. Research and development expenses decreased, while general and administrative expenses also saw a decrease. Monopar projects that its current funds will be sufficient until at least August 31, 2025.

Monopar is focused on developing innovative cancer treatments, including its Phase 1 MNPR-101-Zr for imaging and MNPR-101 radio-immuno-therapeutic for advanced cancers. The company aims to raise additional capital within the next 12 months for ongoing operations and clinical programs. Forward-looking statements reflect optimism for the company’s progress and future plans.



Read more at GlobeNewswire:: Monopar Therapeutics Reports Second Quarter 2024 Financial